The Efficacy of Venlafaxine and Duloxetine in Improving Chemotherapy-Induced Neurotoxicity

Comparison of the Efficacy of Venlafaxine and Duloxetine in Improving Chemotherapy-Induced Neurotoxicity in Cancer Patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20230201057300N1

Enrollment

Registered

2023-02-15

Start date

2018-04-14

Completion date

Unknown

Last updated

2023-03-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chemotherapy-Induced Peripheral Neuropathy.

Interventions

Intervention group: The First Group Was Treated With Venlafaxine at 37.5 mg Daily and Increased to 75 mg if The Patient Tolerated. The Second Group Was Treated With Duloxetine at 30 mg Daily and Incre

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Age 18 to 75 years Incidence of Neuropathy after starting Chemotherapy Cancer Diagnosis Receive Chemotherapy

Exclusion criteria

Exclusion criteria: Having an Underlying Neuropathy Disease such as Diabetes Mellitus Incomplete Treatment Intolerance of the patient due to Drug side effects Death of Patients

Design outcomes

Primary

Measure	Time frame
Severity of Peripheral Neuropathy. Timepoint: Severity of Peripheral Neuropathy at the Beginning of the study then weekly. Method of measurement: NCI- Common Terminology Criteria for Adverse Event- ver3.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFarshid Fardad

Iran University of Medical Sciences

drfardadf@yahoo.com+98 11 5422 8717

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026